市場調査レポート
商品コード
1298837
胃腸用OTC医薬品市場:薬効分類別、適応症別、エンドユーザー別、地域別 2023-2028年Gastrointestinal OTC Drugs Market by Drug Class, Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion Sickness, and Others), End User, and Region 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
胃腸用OTC医薬品市場:薬効分類別、適応症別、エンドユーザー別、地域別 2023-2028年 |
出版日: 2023年06月14日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
|
世界の胃腸用OTC医薬品市場規模は2022年に400億米ドルに達しました。今後、IMARC Groupは、市場は2028年までに524億米ドルに達し、2023~2028年の成長率(CAGR)は4.90%になると予測しています。胃腸疾患の有病率の上昇、消化器系の健康に対する新興国市場の意識の高まり、高度な製剤の最近の市場開拓は、市場を牽引する主な要因のひとつです。
胃腸の一般用医薬品(OTC)とは、胃腸の症状を緩和し、全体的な消化器系の健康を促進する非処方薬を指します。下剤、制酸剤、H2ブロッカー、プロトンポンプ阻害剤(PPI)、制吐剤、腸抗炎症剤、下痢止めなどが含まれます。胃腸用OTC医薬品は、消化不良、便秘、胸やけ、下痢、乗り物酔い、酸逆流、吐き気、過敏性腸症候群(IBS)、腹痛などの治療に広く使われています。費用対効果が高く、便利で簡単に入手できる製品であり、即効性のある緩和をもたらし、患者の快適性を高め、自己管理を可能にします。胃腸用OTC医薬品はまた、腸の健康状態を改善し、有益な細菌を回復させ、将来の合併症を予防し、痛み、腹部膨満感、腹部不快感、嘔吐などの様々な症状の重症度を最小限に抑えるのに役立ちます。
座りがちなライフスタイルや不健康な食習慣による胃腸障害の有病率の上昇は、市場の成長を後押しする重要な要因のひとつです。胃腸用OTC医薬品は、感染症、消化不良、急性下痢、胸やけ、胃食道逆流症(GERD)、便秘、腹部膨満感、つわりなどの治療に広く使用されています。さらに、消化を改善し、腸の健康を促進し、栄養素の適切な分解と吸収を確保するための製品用途の増加は、消化の健康に対する大衆の意識の高まりに起因しており、市場成長の原動力となっています。これに伴い、健康状態を管理し将来の健康合併症を予防するためのセルフケアと消費者のエンパワーメントという新たな動向が、もう一つの成長誘発要因として作用しています。さらに、発泡性錠剤、液剤、懸濁剤、フィルムストリップ、チュアブル製品など、薬剤の効果を高め、吸収を高め、投与回数を減らすことができる高度な製剤が最近開拓されたことも、市場成長にプラスの影響を与えています。これに加えて、ブリスターパック、リシーラブルパウチ、1回投与分包などの便利で旅行しやすいパッケージングのイントロダクションが市場成長を促進しています。これとは別に、非侵襲的な治療に対する消費者の嗜好の高まりが、一般的な消化器系の問題を管理し、即時の救済を提供する製品需要を促進しています。さらに、複数のメーカーによるテレビ(TV)コマーシャル、ソーシャルメディア、インフルエンサーマーケティング、有名人の推薦を通じた積極的なプロモーションやブランディングキャンペーンが市場成長を強化しています。その他、老年人口の増加、消費者の支出能力の増加、eコマースプラットフォームでの製品の容易な入手などが市場成長を促進すると予想されます。
本レポートに掲載されている企業リストは一部です。
The global gastrointestinal OTC drugs market size reached US$ 40 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 52.4 Billion by 2028, exhibiting a growth rate (CAGR) of 4.90% during 2023-2028. The rising prevalence of gastrointestinal disorders, increasing awareness among the masses regarding digestive health, and the recent development of advanced formulations represent some of the key factors driving the market.
Gastrointestinal over-the-counter (OTC) drugs refer to non-prescription medications that alleviate gastrointestinal symptoms and promote overall digestive wellness. It includes laxatives, antacids, H2 blockers, proton pump inhibitors (PPIs), anti-emetics, bowel anti-inflammatory, and anti-diarrheal medications. Gastrointestinal OTC drugs are widely used to treat indigestion, constipation, heartburn, diarrhea, motion sickness, acid reflux, nausea, irritable bowel syndrome (IBS), and abdominal pain. It is a cost-effective, convenient, and easily accessible product that provides immediate relief, enhances patient comfort, and allows self-management. Gastrointestinal OTC drugs also aid in improving gut health, restoring beneficial bacteria, preventing future complications, and minimizing the severity of various symptoms, such as pain, bloating, abdominal discomfort, and vomiting.
The rising prevalence of gastrointestinal disorders due to sedentary lifestyles and unhealthy eating habits is one of the key factors providing a thrust to the market growth. Gastrointestinal OTC drugs are widely used to treat infections, dyspepsia, acute diarrhea, heartburn, gastroesophageal reflux disease (GERD), constipation, bloating, and morning sickness. Furthermore, the increasing product applications to improve digestion, promote gut health, and ensure proper breakdown and absorption of nutrients, owing to the growing awareness among the masses regarding digestive health, is providing an impetus to the market growth. In line with this, the emerging trends of self-care and consumer empowerment to manage well-being and prevent future health complications are acting as another growth-inducing factor. Additionally, the recent development of advanced formulations, such as effervescent tablets, liquids, suspensions, film strips, and chewable products, which enhances the effectiveness of the drugs, increases absorption, and reduces the frequency of dosing, is positively influencing the market growth. Besides this, the introduction of convenient and travel-friendly packaging, such as blister packs, resealable pouches, and single-dose packets, is propelling the market growth. Apart from this, the rising consumer preference for non-invasive treatments is facilitating product demand to manage common digestive issues and provide immediate relief. Moreover, aggressive promotional and branding campaigns by several manufacturers through television (TV) commercials, social media, influencer marketing, and celebrity endorsement is strengthening the market growth. Other factors, including the rising geriatric populations, increasing expenditure capacities of consumers, and easy availability of products across e-commerce platforms, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global gastrointestinal OTC drugs market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on drug class, indication, and end user.
Laxatives
Gastrointestinal Cancer Treatments
Gastric Acid Reducers
Anti-Diarrheal
Proton Pump Inhibitors
H2 Inhibitors
Gastric Acid Neutralizers
Bowel Anti-Inflammatory
Anti-Emetics
The report has provided a detailed breakup and analysis of the gastrointestinal OTC drugs market based on the drug class. This includes laxatives, gastrointestinal cancer treatments, gastric acid reducers, anti-diarrheal, proton pump inhibitors, H2 inhibitors, gastric acid neutralizers, bowel anti-inflammatory, and anti-emetics.
Gastroesophageal Reflux Disease (GERD) or Heartburn
Constipation
Diarrhea
Motion Sickness
Others
A detailed breakup and analysis of the gastrointestinal OTC drugs market based on the indication has also been provided in the report. This includes gastroesophageal reflux disease (GERD) or heartburn, constipation, diarrhea, motion sickness, and others.
Hospitals
Clinics
Others
A detailed breakup and analysis of the gastrointestinal OTC drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and others.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for gastrointestinal OTC drugs. Some of the factors driving the North America gastrointestinal OTC drugs market included the rising prevalence of gastrointestinal disorders, increasing awareness among the masses, and various product innovations.
The report has also provided a comprehensive analysis of the competitive landscape in the global gastrointestinal OTC drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Boehringer Ingelheim GmbH, Johnson & Johnson, Prestige Consumer Healthcare Inc., Purdue Pharma L.P, Sanofi, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.